Image pharmaphorum Editor News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales. News Prostate drug approved for use in non-metastatic cases The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer. News Type 2 diabetes research: fewer side effects from modified m... Scientists have made progress in the quest to find medication for Type 2 diabetes that causes fewer side effects than current treatments. News China strives to lower cost of cancer drugs as disease rates... China is pushing domestic and overseas markets to lower the cost of cancer drugs to make them more accessible. Load more results
News NICE approves neuroblastoma immunotherapy drug for NHS use NICE has approved a drug to treat children with high-risk neuroblastoma within the NHS in England and Wales.
News Prostate drug approved for use in non-metastatic cases The US Food and Drug Administration has approved the drug Xtandi (enzalutamide) to treat men with advanced non-metastatic prostate cancer.
News Type 2 diabetes research: fewer side effects from modified m... Scientists have made progress in the quest to find medication for Type 2 diabetes that causes fewer side effects than current treatments.
News China strives to lower cost of cancer drugs as disease rates... China is pushing domestic and overseas markets to lower the cost of cancer drugs to make them more accessible.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.